Overview

Gender

male

George Miljanich PhD, is a co-founder and Chief Scientific Officer at SiteOne. SiteOne is George’s third start-up. He has been developing ion channel therapeutics and analgesics for over 25 years. In 2010, he co-founded and was founding President and CEO of SiteOne Therapeutics.He is also CEO at Airmid Inc., a clinical-stage company developing treatments for autoimmune disorders.

Prior to Airmid, he was Senior Director and head of analgesia research at Elan Pharmaceuticals, playing a key role in clinical development, FDA approval, and commercialization of the analgesic, PRIALT®. Prior to Elan, he was a co-inventor and co-developer of PRIALT at the Neurex Corporation.

George has a BS and PhD in Chemistry from UC Berkeley and UC Santa Cruz and was a post-doctoral fellow at UC San Francisco, then was Professor of Neurobiology at the University of Southern California. George has authored over 50 scientific publications and is co-inventor on 23 U.S. patents.

He is on the advisory boards of Naurex Pharmaceuticals, Adynxx Pharmaceuticals, and Jazz Pharmaceuticals, all developing and/or marketing treatments for pain. He is also Vice President of the Toxinomics Foundation, which fosters development of toxin-based therapeutics. George was the recipient of the 2012 Ménez Award for his contributions to toxinology.